Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Dateline City:
KENILWORTH, N.J.
Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015
Results Presented for the First Time at ICAAC/ICC 2015 Annual Meeting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the two pivotal Phase 3 clinical studies for
bezlotoxumab, its investigational antitoxin for prevention of Clostridium
difficile (C. difficile) infection recurrence, met their
primary efficacy endpoint: the reduction in C. difficile recurrence
through week 12 compared to placebo, when used in conjunction with
standard of care antibiotics for the treatment of C. difficile.
Language:
English
Contact:
MerckMedia Contacts:Doris Li, 908-246-5701Ian McConnell, 973-901-5722orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news